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ABSTRACT: Here we describe a facile, tandem synthetic
route for indolo[3,2-c]quinolinones, a class of natural alkaloid
analogues of high biological signiﬁcance. A Ugi four-
component reaction with indole-2-carboxylic acid and an
aniline followed by a Pd-catalyzed cyclization yields tetracyclic
indoloquinolines in good to moderate yields. Commercially
available building blocks yield highly diverse analogues in just
two simple steps.
Exploring better synthetic strategies to obtain naturalproducts, and analogues/skeletons thereof, are at the
very heart of synthetic organic chemistry and medicinal
chemistry.1 Approaches achieving atom economy are highly
sought after, oﬀering various advantages, minimization of
waste, time, and resources. Multicomponent reactions (MCRs)
are such an advanced class of organic reactions which, opposite
to classical organic reactions, allow for the easy, fast, and
eﬃcient generation of chemical diversity in just one assembly
step.2 The scaﬀold diversity of MCRs and the window in
chemical space have been undoubtedly recognized by the
synthetic community in industry and academia as a great tool
to design and discover a variety-oriented series of building
blocks with potentially interesting biological activities.2a
Indole fused polyheterocycles, as constituents of diverse
natural alkaloids and pharmaceutical agents, have drawn much
attention from organic and bioorganic chemists during the past
several decades.3 Among these, 2,3-fused indoles are of
particular interest as they are a part of a large number of
natural products of biological interest such as reserpine
(reuptake inhibitor),4a fumitremorgin C (BCRP-speciﬁc
inhibitor),4b evodiamine (anticancer),4c and terpendole E
(KSP inhibitor) (Figure 1).4d
Indoloquinolinones are very important in the fused indole
family due to their wide occurrence in numerous bioactive
natural products.5 Natural products containing the indoloqui-
nolinone scaﬀold show diverse biological and pharmacological
activities, such as eﬀective DNA intercalators5a and inhibition
of Plasmodium falciparum cyclin-dependent protein kinase as
potential antimalarial agents.5b This tetracyclic structure can
also be utilized as useful building blocks for the synthesis of
natural products such as isocryptolepine6 and many other
potential antineoplastics.5a
The ubiquity of the indoloquinolinone scaﬀold in com-
pounds that exhibit promising biological and pharmacological
properties inspire research into developing eﬃcient methods
for their construction.7 The Wang group disclosed an eﬃcient
synthesis of indolo[3,2-c]quinolinones from N-(o-bromophen-
yl)-3-indolecarboxamide using a Pd-catalyst (Scheme 1, cutoﬀ
a). The bromo group on the N-aryl moiety was crucial for the
success of this reaction.7a The skeleton can also be assembled
from 3-oxo-3-phenylpropanoate derivatives and substituted
anilines that involves Pd/Cu catalyzed C−C bond formation
and I(III)-mediated oxidative C−N bond formation which was
reported by Zhang in 2013 (cutoﬀ b).7b Doyle and co-workers
synthesized the skeleton from an indole-3-carboxylate
derivative via intramolecular lactamization (cutoﬀ c).7c The
indoloquinolinone skeleton can also be constructed through a
microwave-assisted thermal electrocyclization of a phenyl
isocyanate (cutoﬀ d).7d Furthermore, the Xu group reported
a base-free process to access the skeleton via a palladium-
catalyzed intramolecular cross dehydrogenative coupling
(CDC) reaction (cutoﬀ e).7e The indoloquinolinone skeleton
can also be constructed through an intramolecular displace-
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Figure 1. Some bioactive 2,3-fused indole compounds.
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ment reaction involving an aromatic ﬂuorine (cutoﬀ f).7f The
CuI-catalyzed photochemical or thermal reaction of 3-(2-
azidobenzylidene)-lactams can also provide the desired
indoloquinolinone skeleton (cutoﬀ g).7g While these methods
are useful for the synthesis of valuable indolo[3,2-c]-
quinolinones, they mainly rely on the manipulation of
prefunctionalized substrates and overall require multistep
transformations. Moreover, most of them suﬀer from a limited
substrate scope and poor functional group compatibility and
require protection of the indole NH. From the perspective of
atom economy and step eﬃciency, an ideal synthesis that could
overcome these shortcomings is still highly desired.
Recently, Lingkai and his colleagues developed an eﬃcient
method to construct indolo[3,2-c]quinolinones starting from
indole-2-carboxamides in the presence of a Pd-catalyst.8 From
our point of view, the methodology is ideally suitable for a
multicomponent reaction. Therefore, our aim is to use easily
accessible starting materials in a Ugi four-component reaction
followed by a tandem/sequential Pd(OAc)2-catalyzed dual
C(sp2)−H functionalization of the Ugi products toward
indolo[3,2-c]quinolinone analogues, involving a 1,2-acyl
migration. To the best of our knowledge, this is the ﬁrst
study on the use of MCR in the synthesis of an indolo[3,2-
c]quinolinone library.
Isocyanide-based multicomponent reactions (IMCRs) have
attracted much attention, due to the fact that versatile
functional groups can be introduced in the MCR adducts,
which can undergo further condensations or cyclization
reactions leading to an array of structurally diverse scaﬀolds.9
In this study, starting from the Ugi-4CR of aniline 1a,
benzaldehyde 2a, indole-2-carboxylic acid 3a, and tert-butyl
isocyanide 4a in methanol at room temperature resulted in the
corresponding Ugi adduct 5a in a good yield of 83% after 12 h.
With compound 5a in hand, we were keen to investigate the
C−H functionalization and optimize the reaction conditions
(Table 1). When the reaction was carried out in the presence
of 10 mol % of Pd(OAc)2 using 3.0 equiv of Cu(OAc)2 as the
oxidant in DMF at 140 °C under N2 for 9 h, the desired
product 6a was obtained in 49% yield (entry 1). Although
Pd(TFA)2 (51% yield, entry 2) was slightly superior to
Pd(OAc)2, we chose Pd(OAc)2 as the catalyst for further
scope and limitation studies from the point of view of
Scheme 1. Synthetic Routes of Indolo[3,2-c]quinolinones
through Diﬀerent Cutoﬀs
Table 1. Optimization Studies for the Formation of 6aa,b
entry catalyst (mol %) [O] (equiv) additive (equiv) solvent T (°C) product yield (%) 6a
1c Pd(OAc)2 (10) Cu(OAc)2 (3) − DMF 140 49
2c Pd(TFA)2 (10) Cu(OAc)2 (3) − DMF 140 51
3d Pd(OAc)2 (10) Cu(OAc)2 (3) − DMF 140 55
4e Pd(OAc)2 (10) Cu(OAc)2 (3) − DMF 140 62
5 Pd(OAc)2 (10) Cu(OAc)2 (3) PivOH (4) DMF 140 71
6 Pd(OAc)2 (10) Cu(OAc)2 (3) PivOH (2) DMF 140 67
7 Pd(OAc)2(10) Cu(OAc)2(3) PivOH (6) DMF 140 78
8f Pd(OAc)2 (10) Cu(OAc)2 (3) PivOH (6) DMF 140 76
9 Pd(OAc)2 (10) CuBr2 (3) PivOH (6) DMF 140 trace
10 Pd(OAc)2 (10) Cu(NO3)2 (3) PivOH (6) DMF 140 trace
11 Pd(OAc)2 (5) Cu(OAc)2 (3) PivOH (6) DMF 140 67
12 Pd(OAc)2 (10) Cu(OAc)2 (2) PivOH (6) DMF 140 73
13 Pd(OAc)2 (10) Cu(OAc)2 (1) PivOH (6) DMF 140 58
14 Pd(OAc)2 (10) Cu(OAc)2 (3) PivOH (6) DMF 120 32
15 Pd(OAc)2 (10) Cu(OAc)2 (3) PivOH (6) DMF 160 75
16 Pd(OAc)2 (10) Cu(OAc)2 (3) PivOH (6) CH3CN 140 trace
17 Pd(OAc)2 (10) Cu(OAc)2 (3) PivOH (6) 1,4-Dioxane 140 trace
18 Pd(OAc)2 (10) Cu(OAc)2 (3) PivOH (6) DMAc 140 46
19 Pd(OAc)2 (10) − PivOH (6) DMF 140 trace
20 − Cu(OAc)2 (3) PivOH (6) DMF 140 ND
aThe Ugi-reaction was carried out using 1a (1.0 mmol), 2a (1.0 mmol), 3a (1.05 mmol), and 4a (1.05 mmol) in MeOH (1 M) for 12 h at rt.
bReaction conditions: 5a (0.3 mmol), Pd(OAc)2 (10 mol %), [O] (0.9 mmol), PivOH (1.8 mmol), solvent (1 mL), 140 °C, N2, isolated yields.
cSolvent (6 mL). dSolvent (3 mL). eSolvent (1 mL). fReaction time: 16 h.
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economy. Reducing the amount of solvent resulted in higher
yields (entries 3−4). To our delight, the desired product 6a
was formed in 71% yield with the addition of 4.0 equiv of
pivalic acid (PivOH) (entry 5). Decreasing the amount of
PivOH to 2.0 equiv aﬀorded 6a in 67% yield (entry 6).
However, further increasing the amount of PivOH to 6.0 equiv
improved the yield of 6a to 78% (entry 7). Increasing the
reaction time did not help improve the outcome of the product
(entry 8). Other oxidants such as CuBr2 and Cu(NO3)2 failed
to give the desired product 6a (entries 9−10). Reducing the
amount of Pd(OAc)2 to 5 mol % gave a lower yield (67%) of
6a (entry 11). When the amount of Cu(OAc)2 was reduced to
2.0 or 1.0 equiv, the yield of 6a was decreased to 73% and 58%,
respectively (entries 12 and 13). The yield of 6a dramatically
decreased to 32% at a lower temperature of 120 °C (entry 14).
We also tested a higher temperature of 160 °C but without any
increase of the yield (entry 15). Other solvents were also
examined such as acetonitrile, 1,4-dioxane, and DMAc (N,N-
dimethylacetamide). It was found that DMF was the best
solvent for this reaction among the selected solvents (entry 7
vs entries 16−18). Notably, no desired product was obtained
in the absence of Pd(OAc)2 or Cu(OAc)2 (entries 19 and 20).
Finally, the optimized reaction conditions were concluded to
be 10 mol % Pd(OAc)2, 3.0 equiv of Cu(OAc)2, and 6.0 equiv
of PivOH in DMF (1 mL) at 140 °C under N2 (entry 7).
With the optimal conditions in hand, a series of Ugi
products were synthesized in good to excellent yields and were
examined to determine the scope of cyclization reaction by
reacting substituted anilines with diﬀerent aldehydes/ketones,
isocyanides, and indole-2-carboxylic acids in methanol
followed by Pd(OAc)2-catalyzed C(sp
2)−H functionalization
to furnish the corresponding library 6a−r (Scheme 2). All the
substrates 1, 2, 3, and 4 led to the expected indolo[3,2-
c]quinolinone products 6a−r in 35−78% yields in two steps.
Substituted anilines with electron-donating groups such as p-
methyl (1c), p-anisole (1e), 3,5-dimethyl (1f), p-NHBoc (1k),
and p-methoxy (1l) reacted smoothly with 58%, 64%, 42%,
49%, and 72% yields, respectively. Electron-withdrawing
substituents such as chloro and ﬂuoro reacted nicely to give
the cyclized products in 55% and 59% yields, respectively (6b,
6g). Notably, the bromo or iodo group was cleaved in the
presence of a palladium catalyst to give the major product 6a
when 4-bromoaniline or 4-iodoaniline was employed in the
cyclization reactions. Besides, commercially available 5-chloro,
5-methoxy, and 6-methoxy substituted indole-2-carboxylic acid
(3j, 3m, 3o) reacted to give the expected product in moderate
to good yields. Surprisingly, N-methyl substituted indole-2-
carboxylic acid (3r) also formed the polyheterocycle in 65%
yield, which was not the case with the substrate of N,1-
dimethyl-N-phenyl-1H-indole-2-carboxamide.8 Scheme 2
clearly indicates that there are no electronic or steric eﬀects
on the outcome of the reaction.
After successfully demonstrating the cyclization reactions
with diﬀerent anilines and indole-2-carboxylic acids, we then
focused on diﬀerent aldehydes/ketones and isocyanides.
Paraformaldehyde was utilized in most cases and results in
good yields. Benzaldehyde and p-nitrobenzaldehyde also
reacted smoothly to achieve the cyclized products 6d, 6h in
40% and 35% yields, respectively. It is worth mentioning that
the cyclic ketone reacted without any interruption to obtain a
moderate yield (6i). Furthermore, the benzyl isocyanide (4k)
and substituted benzyl isocyanides with electron-donating
groups such as p-methoxy (4p), 2,3-dimethoxy (4o) reacted
smoothly with 49%, 59%, and 65% yields, respectively. The
Ugi adduct bearing a 1-methoxy-4-ethylbenzene substituent on
the amide moiety also underwent the reaction, aﬀording the
highly strained polycyclic indole compound 6j in good yield.
Similarly, aliphatic cyclic and branched isocyanides (6n, 6m,
6q) also furnished the diﬀerent tetraheterocycles in good
yields.
Several structures have been conﬁrmed by X-ray single-
crystal analyses (Figure 2 and Supporting Information). The
following interesting motifs could be observed in the solid
state: the scaﬀold in general is ﬂat, and therefore, stocking
Scheme 2. Synthesis of Indolo[3,2-c]quinolinones 6a,b,c,d
aThe amine, aldehyde, isocyanide, and acid components are depicted
with pink, blue, red, and green color, respectively. bThe Ugi-reaction
was carried out using 1 (1.0 mmol), 2 (1.0 mmol), 3 (1.05 mmol),
and 4 (1.05 mmol) in MeOH (1M) for 12 h at rt. cReaction
conditions: 5 (0.3 mmol), Pd(OAc)2 (10 mol %), Cu(OAc)2 (0.9
mmol), PivOH (1.8 mmol), DMF (1.0 mL), 140 °C, 9 h, isolated
yields. Under nitrogen. dYield refers to the puriﬁed products.
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interactions with neighboring molecules are always observed
(Supporting Information, Figure S2).
Furthermore, the scalability of this method was investigated
(Scheme 3). A four-component reaction of 4-chloroaniline 1b,
paraformaldehyde 2b, indole-2-carboxylic acid 3b, and tert-
butyl isocyanide 4b was conducted in 10 mmol scale, while the
product 6b could be obtained in 42% yield (1.6 g) via two
steps. Therefore, this Ugi reaction of indole-2-carboxylic acid
and the following Pd-catalyzed dual C(sp2)−H functionaliza-
tion could be easily scaled up demonstrating it is a practical
method.
To gain further insight into the reaction mechanism, a
radical trapping experiment as a control experiment was
examined (Scheme 4). The reaction was not inhibited by the
addition of 3.0 equiv of TEMPO, and 6a was still obtained in
45% yield (Scheme 4a). The results suggested that a radical
pathway was most likely not involved in this reaction. By
changing the oxidant from copper acetate to oxygen, 6a could
still be obtained in 28% yield (Scheme 4b). However, without
palladium acetate, product 6a could not be observed (Scheme
4c). These results proved again that copper acetate might serve
only as an oxidant.
A plausible mechanism of the cyclization path was explained
based on the previous report as shown in Scheme 5.8 After
obtaining the Ugi adduct 5a, Pd(OAc)2 attacks the indole to
give the iminium intermediate A, which undergoes a
nucleophilic attack of the N-aryl to the iminium moiety
which forms the intermediate B. Then B is further converted
to the intermediate C via a nucleophilic addition process.
Subsequently, the formed C undergoes 1,2-acyl migration to
give intermediate D, which after protonation and oxidative
aromatization gives the product 6a.
Moreover, we were also interested in potential biological
applications of the synthesized compounds. For this aim, all
the compounds were docked in the cocrystal structure of
human proto-oncogene serine threonine kinase (PIM1) [PDB
code 3CY2]. The original cocrystallized ligand binds in a non-
ATP mimetic binding mode. In the docking poses, we noticed
that our ligands ﬁt the pocket nicely and there is a good
overlap of the indole moieties (nonsubstituted or with Cl- or
OMe- substituents) of the docking compounds with the
original ligand. The pyridone moiety is reversed in the docked
poses in most of the cases; however, this carbonyl group did
not participate in hydrogen bonds in the original ligand either.
Interestingly, we observed that the conformation of the
piperidine moiety was mimicked in the 6a by the tert-butyl
acetamide and the NH-moiety formed a hydrogen bond with
the carbonyl group of Asn172, similar to one of the
interactions of the original piperidine (Figure 3A). In the
case of the ketone-derivated ligand 6i, the NH-moiety of the
tert-butyl acetamide is able to form a hydrogen bond with
Glu171, whereas the cyclopentane ring is ﬁlling a more
hydrophobic part of the pocket, forming van der Waals
interactions with Phe49 (Figure 3B). We hypothesize that
these compounds could have potential as kinase inhibitors
(Figure 3).
Figure 2. X-ray structures of selected products; crystallographic data
have been deposited with the Cambridge Crystallographic Data
Centre as supplementary publication nos.: CCDC1912181 (6b) and
CCDC1912182 (6c).
Scheme 3. Gram-Scale Reaction
Scheme 4. Control Experiments
Scheme 5. Proposed Reaction Mechanism
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■ CONCLUSIONS
In summary, an indolo[3,2-c]quinolinone library was success-
fully established based on MCR starting from commercially
available materials. Diversity can be achieved through the
aniline, aldehyde/ketone, isocyanide, and indole-2-carboxylic
acid, all four components. Regarding potential applications,
docking studies indicate that these types of derivatives could be
useful as kinase inhibitors, and biological work is ongoing and
will be reported in due course.
■ EXPERIMENTAL SECTION
General Information. Nuclear magnetic resonance spectra were
recorded on a Bruker Avance 500 spectrometer. Chemical shifts for
1H NMR were reported relative to TMS (δ 0 ppm) or internal solvent
peak (CDCl3 δ 7.26 ppm, DMSO-d6 δ 2.50 ppm or CD3OD δ 3.31
ppm), and coupling constants were in hertz (Hz). The following
abbreviations were used for spin multiplicity: s = singlet, d = doublet,
t = triplet, dt = double triplet, ddd = doublet of double doublet, m =
multiplet, and br = broad. Chemical shifts for 13C NMR reported in
ppm relative to the solvent peak (CDCl3 δ 77.23 ppm, DMSO δ 39.52
ppm, CD3OD δ 49.00 ppm). Flash chromatography was performed
on a Grace Reveleris X2 using Grace Reveleris Silica columns (12 g),
and a gradient of petroleum ether/ethyl acetate (0−100%) or
dichloromethane/methanol (0−20%) was applied. Thin layer
chromatography was performed on Fluka precoated silica gel plates
(0.20 mm thick, particle size 25 μm). Reagents were available from
commercial suppliers and used without any puriﬁcation unless
otherwise noted. All isocyanides were made in house by performing
the Ugi procedure. Other reagents were purchased from Sigma-
Aldrich, ABCR, Acros, Fluorochem, and AK Scientiﬁc and were used
without further puriﬁcation. Mass spectra were measured on a Waters
Investigator Supercritical Fluid Chromatograph with a 3100 MS
Detector (ESI) using a solvent system of methanol and CO2 on a
Viridis silica gel column (4.6 mm × 250 mm, 5 μm particle size) and
reported as (m/z). High resolution mass spectra (HRMS) were
recorded using an LTQ-Orbitrap-XL (Thermo Fisher Scientiﬁc; ESI
pos. mode) at a resolution of 60000@m/z400. Electrospray ionization
mass spectra (ESI-MS) were recorded on a Waters Investigator
Semiprep 15 SFC-MS instrument. Melting points were obtained on a
melting point apparatus and were uncorrected. Yields given refer to
chromatographically puriﬁed and spectroscopically pure compounds
unless otherwise stated.
General Experimental Procedure and Characterization.
General Procedure A. A solution of aldehyde or ketone 1 (1.0
mmol) and amine 2 (1.0 mmol) in methanol (1 mL) was stirred at
room temperature for 30 min. Subsequently, isocyanide 3 (1.05
mmol) and indole-2-carboylic acid 4 (1.05 mmol) were added and the
reaction was stirred at room temperature overnight. Reaction progress
was monitored via TLC and SFC-MS. Upon completion of the
reaction, the mixture was concentrated in vacuo and puriﬁed by
column chromatography to give the desired product 5.
General Procedure B. Ugi adduct 5 (0.3 mmol), Pd(OAc)2 (0.03
mmol), Cu(OAc)2 (0.9 mmol), PivOH (1.8 mmol), and DMF (1
mL) were placed in a ﬂask under N2. After the completion of the
addition, the reaction mixture was allowed to react at 140 °C in an oil
bath for 9 h. Then, the reaction mixture was cooled to room
temperature, treated with H2O, and then extracted with EA. The
combined organic layers were washed with brine and dried over
anhydrous Na2SO4. After removal of the EA, the residue was puriﬁed
by ﬂash chromatography to aﬀord the product 6.
Gram-Scale Synthesis of 6b. An oven-dried 50 mL ﬂask equipped
with a magnetic stirrer bar was charged with 4-chloroaniline (1.27 g,
10 mmol) and paraformaldehyde (300 mg, 10 mmol). 15 mL of
MeOH were added, and the reaction was stirred for 30 min. Then
indole-2-carboxylic acid (1.69 g, 10.5 mmol) was added followed by
tert-butyl isocyanide (872 mg, 10.5 mmol). The mixture was stirred at
rt for 24 h. Solvent was removed under vacuum, and the residue was
puriﬁed by silica gel column chromatography using ethyl acetate/
petroleum ether (v/v, 1:1) as eluent to give Ugi product 5b (3.14 g,
82%). Subsequently, Ugi adduct 5b (3.14 g, 8.2 mmol), Pd(OAc)2
(184 mg, 0.82 mmol), Cu(OAc)2 (4.5 g, 25 mmol), PivOH (5 g, 49
mmol), and DMF (20 mL) were placed in a 50 mL ﬂask under N2.
After the completion of the addition, the reaction mixture was allowed
to react at 140 °C in an oil bath for 12 h. Then, the reaction mixture
was cooled to room temperature, was treated with H2O, and then
extracted with EA. The combined organic layers were washed with
brine and dried over anhydrous Na2SO4. After removal of the EA, the
residue was puriﬁed by column chromatography (silica gel; 60% ethyl
acetate in petroleum ether) to aﬀord the product 6b (1.6 g, 51%) as
an oﬀ-white solid.
N-(2-(tert-Butylamino)-2-oxoethyl)-N-phenyl-1H-indole-2-car-
boxamide (5a). Synthesized according to procedure A in 1 mmol
scale, with puriﬁcation of the crude product by column chromatog-
raphy (silica gel; 40% ethyl acetate in petroleum ether) to aﬀord 5a
(287 mg, 82%) as a yellow solid. 1H NMR (500 MHz, Chloroform-d)
δ 9.66 (s, 1H), 7.58−7.48 (m, 3H), 7.48−7.35 (m, 4H), 7.31−7.22
(m, 1H), 7.05 (ddd, J = 7.9, 6.9, 0.9 Hz, 1H), 6.37 (s, 1H), 5.36 (d, J
= 2.1 Hz, 1H), 4.45 (s, 2H), 1.38 (s, 9H) ppm. 13C{1H} NMR (126
MHz, Chloroform-d) δ 167.6, 162.7, 142.9, 135. 6, 130.1, 129.0,
128.7, 128.4, 127.6, 125.0, 122.4, 120.4, 111.6, 108.2, 56.5, 51.4, 28.8
ppm.
N-(2-(tert-Butylamino)-2-oxoethyl)-N-(4-chlorophenyl)-1H-in-
dole-2-carboxamide (5b). Synthesized according to procedure A in 1
mmol scale, with puriﬁcation of the crude product by column
chromatography (silica gel; 50% ethyl acetate in petroleum ether) to
aﬀord 5b (326 mg, 85%) as a yellow solid. 1H NMR (500 MHz,
Chloroform-d) δ 9.52 (s, 1H), 7.50−7.44 (m, 3H), 7.43−7.36 (m,
3H), 7.32−7.24 (m, 1H), 7.07 (t, J = 7.5 Hz, 1H), 6.21 (s, 1H), 5.47
(d, J = 2.1 Hz, 1H), 4.39 (s, 2H), 1.28 (s, 9H). 13C{1H} NMR (126
Figure 3. (A) Docking poses. Top left: Overlap of compound 6c
(magenta sticks) with the ligand (yellow sticks) of PDB 3CY2. Top
right: hydrogen bonds (yellow dots) of compound 6c (magenta
sticks) with Asn172 (green sticks). (B) Bottom left: Overlap of
compound 6i (purple sticks) with the ligand (yellow sticks) of PDB
3CY2. Bottom right: hydrogen bonds (black yellow dots) of
compound 6i (purple sticks) with Glu171 (green sticks).
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MHz, Chloroform-d) δ 167.6, 162.7, 142.9, 135.6, 130.1, 129.0, 128.7,
128.4, 127.6, 125.0, 122.4, 120.4, 111.6, 108.2, 56.5, 51.4, 28.8 ppm.
N-(2-(tert-Butylamino)-2-oxoethyl)-N-(p-tolyl)-1H-indole-2-car-
boxamide (5c). Synthesized according to procedure A in 1 mmol
scale, with puriﬁcation of the crude product by column chromatog-
raphy (silica gel; 40% ethyl acetate in petroleum ether) to aﬀord 5c
(265 mg, 73%) as a white solid. 1H NMR (500 MHz, Chloroform-d)
δ 9.56 (s, 1H), 7.44−7.39 (m, 2H), 7.30−7.26 (m, 5H), 7.08−7.02
(m, 1H), 6.38 (s, 1H), 5.41 (d, J = 2.1 Hz, 1H), 4.42 (s, 2H), 2.47 (s,
3H), 1.39 (s, 9H) ppm. 13C{1H} NMR (126 MHz, Chloroform-d) δ
167.9, 162.9, 140.2, 139.1, 137.2, 135.6, 130.7, 128.6, 128.0, 127.6,
125.0, 122.4, 120.4, 111.7, 109.9, 108.4, 56.6, 51.5, 28.8, 21.3 ppm.
N-(2-(tert-Butylamino)-2-oxo-1-phenylethyl)-N-phenyl-1H-in-
dole-2-carboxamide (5d). Synthesized according to procedure A in 1
mmol scale, with puriﬁcation of the crude product by column
chromatography (silica gel; 60% ethyl acetate in petroleum ether) to
aﬀord 5d (383 mg, 90%) as a yellow solid. 1H NMR (500 MHz,
Chloroform-d) δ 9.35 (s, 1H), 7.36 (q, J = 6.0, 4.8 Hz, 3H), 7.33 (s,
1H), 7.29 (s, 2H), 7.27−7.23 (m, 5H), 7.23−7.20 (m, 1H), 7.05−
6.92 (m, 1H), 6.11 (d, J = 3.7 Hz, 1H), 5.79 (s, 1H), 5.16−5.01 (m,
1H), 3.52 (s, 1H), 1.38 (s, 9H) ppm. 13C{1H} NMR (126 MHz,
Chloroform-d) δ 168.6, 162.3, 140.1, 135.3, 134.5, 131.1, 130.4,
128.7, 128.5, 128.4, 127.7, 124.7, 122.4, 120.2, 111.4, 107.7, 67.3,
51.7, 28.7 ppm.
N-(2-(tert-Butylamino)-2-oxoethyl)-N-(4-phenoxyphenyl)-1H-in-
dole-2-carboxamide (5e). Synthesized according to procedure A in 1
mmol scale, with puriﬁcation of the crude product by column
chromatography (silica gel; 50% ethyl acetate in petroleum ether) to
aﬀord 5e (331 mg, 75%) as a yellow solid. 1H NMR (500 MHz,
Chloroform-d) δ 9.33 (s, 1H), 7.49−7.33 (m, 6H), 7.30 (d, J = 1.1
Hz, 1H), 7.23−7.18 (m, 1H), 7.16−7.06 (m, 5H), 6.32 (s, 1H), 5.45
(dd, J = 2.2, 1.0 Hz, 1H), 4.40 (s, 2H), 1.40 (s, 9H) ppm. 13C{1H}
NMR (126 MHz, Chloroform-d) δ 167.7, 162.6, 157.9, 156.4, 137.6,
135.4, 130.0, 129.9, 128.6, 127.7, 125.1, 124.1, 122.4, 120.6, 119.7,
119.4, 111.6, 108.1, 56.6, 51.4, 28.8 ppm.
N-(2-(tert-Butylamino)-2-oxoethyl)-N-(3,5-dimethylphenyl)-1H-
indole-2-carboxamide (5f). Synthesized according to procedure A in
1 mmol scale, with puriﬁcation of the crude product by column
chromatography (silica gel; 35% ethyl acetate in petroleum ether) to
aﬀord 5f (287 mg, 76%) as a yellow solid. 1H NMR (500 MHz,
Chloroform-d) δ 9.55 (s, 1H), 7.52−7.34 (m, 2H), 7.27 (d, J = 11.5
Hz, 1H), 7.15 (d, J = 16.5 Hz, 1H), 7.03 (d, J = 30.8 Hz, 3H), 6.41 (s,
1H), 5.46 (s, 1H), 4.41 (s, 2H), 2.37 (s, 6H), 1.39 (s, 9H) ppm.
13C{1H} NMR (126 MHz, Chloroform-d) δ 167.9, 162.6, 142.5,
139.9, 135.5, 130.7, 128.7, 127.7, 125.8, 124.9, 122.4, 120.4, 111.6,
108.2, 56.7, 51.3, 28.8, 21.3 ppm.
N-(2-(tert-Butylamino)-2-oxoethyl)-N-(4-ﬂuorophenyl)-1H-in-
dole-2-carboxamide (5g). Synthesized according to procedure A in 1
mmol scale, with puriﬁcation of the crude product by column
chromatography (silica gel; 50% ethyl acetate in petroleum ether) to
aﬀord 5g (331 mg, 90%) as a white solid. 1H NMR (500 MHz,
Chloroform-d) δ 9.47 (s, 1H), 7.46−7.38 (m, 4H), 7.30−7.25 (m,
1H), 7.20 (dd, J = 9.2, 7.9 Hz, 2H), 7.07 (ddd, J = 8.0, 6.9, 1.0 Hz,
1H), 6.23 (s, 1H), 5.36 (t, J = 1.3 Hz, 1H), 4.39 (s, 2H), 1.38 (s, 9H)
ppm. 13C{1H} NMR (126 MHz, Chloroform-d) δ 167.5, 163.5, 161.6,
138.9 (d, J = 3.4 Hz), 135.5, 130.4 (d, J = 8.7 Hz), 128.5, 127.6,
125.1, 122.5, 120.6, 117.1 (d, J = 22.6 Hz), 111.6, 108.1, 56.4, 51.5,
28.8 ppm.
N-(2-(tert-Butylamino)-1-(4-nitrophenyl)-2-oxoethyl)-N-phenyl-
1H-indole-2-carboxamide (5h). Synthesized according to procedure
A in 1 mmol scale, with puriﬁcation of the crude product by column
chromatography (silica gel; 35% ethyl acetate in petroleum ether) to
aﬀord 5h (400 mg, 85%) as yellow solid. 1H NMR (500 MHz,
Chloroform-d) δ 9.33 (s, 1H), 8.15−8.06 (m, 2H), 7.52−7.47 (m,
2H), 7.44 (ddd, J = 8.6, 4.9, 1.3 Hz, 1H), 7.41−7.32 (m, 4H), 7.29 (d,
J = 1.2 Hz, 1H), 7.26 (ddt, J = 8.3, 7.0, 1.3 Hz, 1H), 7.03 (ddd, J =
8.0, 6.9, 1.1 Hz, 1H), 6.20 (d, J = 10.0 Hz, 2H), 5.15 (dd, J = 2.2, 1.0
Hz, 1H), 1.41 (s, 9H) ppm. 13C{1H} NMR (126 MHz, Chloroform-
d) δ 167.6, 162.6, 147.7, 141.6, 139.6, 135.5, 131.2, 130.7, 129.6,
129.4, 128.7, 127.6, 125.2, 123.4, 122.5, 120.5, 111.5, 108.2, 66.3,
52.0, 28.7 ppm.
N-(1-(tert-Butylcarbamoyl)cyclopentyl)-N-phenyl-1H-indole-2-
carboxamide (5i). Synthesized according to procedure A in 1 mmol
scale, with puriﬁcation of the crude product by column chromatog-
raphy (silica gel; 40% ethyl acetate in petroleum ether) to aﬀord 5i
(262 mg, 65%) as a yellow solid. 1H NMR (500 MHz, Chloroform-d)
δ 9.31 (s, 1H), 7.60−7.51 (m, 3H), 7.47−7.42 (m, 2H), 7.35 (ddt, J =
7.3, 1.9, 1.0 Hz, 2H), 7.23 (ddd, J = 8.2, 7.0, 1.1 Hz, 1H), 7.01 (ddd, J
= 7.9, 6.8, 0.9 Hz, 1H), 6.36 (s, 1H), 4.92 (dd, J = 2.1, 1.0 Hz, 1H),
2.50−2.41 (m, 2H), 1.93−1.83 (m, 2H), 1.77−1.58 (m, 4H), 1.41 (s,
9H) ppm. 13C{1H} NMR (126 MHz, Chloroform-d) δ 173.0, 162.6,
140.2, 135.1, 130.9, 130.1, 129.6, 129.3, 127.7, 124.7, 122.3, 120.2,
111.4, 107.0, 75.3, 51.0, 36.9, 28.7, 23.7 ppm.
5-Chloro-N-(2-((4-methoxyphenethyl)amino)-2-oxoethyl)-N-
phenyl-1H-indole-2-carboxamide (5j). Synthesized according to
procedure A in 1 mmol scale, with puriﬁcation of the crude product
by column chromatography (silica gel; 40% ethyl acetate in petroleum
ether) to aﬀord 5j (406 mg, 88%) as a yellow solid. 1H NMR (500
MHz, Chloroform-d) δ 9.38 (s, 1H), 7.54−7.42 (m, 3H), 7.39−7.32
(m, 2H), 7.25−7.16 (m, 3H), 7.13−7.08 (m, 2H), 6.74−6.66 (m,
2H), 6.42 (s, 1H), 5.18 (dd, J = 2.1, 1.1 Hz, 1H), 4.45 (s, 2H), 3.62
(d, J = 0.8 Hz, 3H), 3.58 (q, J = 6.4 Hz, 2H), 2.81 (t, J = 6.7 Hz, 2H)
ppm. 13C{1H} NMR (126 MHz, Chloroform-d) δ 168.2, 162.2, 158.3,
142.4, 133.7, 130.5, 130.1, 129.8, 129.7, 129.2, 128.5, 128.2, 126.1,
125.5, 121.6, 114.0, 112.7, 107.5, 55.6, 55.1, 40.6, 34.5 ppm.
tert-Butyl (4-(N-(2-(Benzylamino)-2-oxoethyl)-1H-indole-2-
carboxamido)phenyl)carbamate (5k). Synthesized according to
procedure A in 1 mmol scale, with puriﬁcation of the crude product
by column chromatography (silica gel; 40% ethyl acetate in petroleum
ether) to aﬀord 5k (369 mg, 74%) as a yellow solid. 1H NMR (500
MHz, Chloroform-d) δ 9.24 (s, 1H), 7.53−7.47 (m, 2H), 7.43 (dd, J
= 8.1, 1.1 Hz, 1H), 7.38 (dt, J = 8.3, 1.1 Hz, 1H), 7.36−7.32 (m, 2H),
7.31−7.23 (m, 6H), 7.05 (ddd, J = 8.1, 6.9, 1.0 Hz, 1H), 6.78 (t, J =
5.9 Hz, 1H), 6.71 (s, 1H), 5.48 (dd, J = 2.2, 1.0 Hz, 1H), 4.54−4.50
(m, 4H), 1.58 (s, 9H) ppm. 13C{1H} NMR (126 MHz, Chloroform-
d) δ 168.5, 162.8, 152.5, 139.1, 138.0, 137.2, 135.5, 129.0, 128.7,
128.5, 127.7, 127.7, 127.5, 125.0, 122.6, 120.5, 119.3, 111.5, 108.4,
55.8, 43.6, 28.4 ppm.
N-(2-(tert-Butylamino)-2-oxoethyl)-6-methoxy-N-(4-methoxy-
phenyl)-1H-indole-2-carboxamide (5l). Synthesized according to
procedure A in 1 mmol scale, with puriﬁcation of the crude product
by column chromatography (silica gel; 60% ethyl acetate in petroleum
ether) to aﬀord 5l (377 mg, 92%) as a yellow solid. 1H NMR (500
MHz, Chloroform-d) δ 9.58 (s, 1H), 7.35−7.25 (m, 2H), 7.05−6.97
(m, 2H), 6.83 (d, J = 2.2 Hz, 1H), 6.72 (dd, J = 8.8, 2.2 Hz, 1H), 6.44
(d, J = 3.7 Hz, 1H), 5.32 (s, 1H), 4.40 (d, J = 1.9 Hz, 2H), 3.90 (s,
3H), 3.83 (s, 3H), 1.36 (s, 9H) ppm. 13C{1H} NMR (126 MHz,
Chloroform-d) δ 168.0, 162.8, 159.8, 158.6, 135.7, 129.5, 127.7,
123.2, 122.1, 115.2, 112.0, 108.5, 93.3, 56.7, 55.6, 55.5, 51.3, 28.8
ppm.
N-(2-(Butylamino)-2-oxoethyl)-5-methoxy-N-(p-tolyl)-1H-indole-
2-carboxamide (5m). Synthesized according to procedure A in 1
mmol scale, with puriﬁcation of the crude product by column
chromatography (silica gel; 85% ethyl acetate in petroleum ether) to
aﬀord 5m (350 mg, 89%) as a yellow solid. 1H NMR (500 MHz,
Chloroform-d) δ 9.53 (s, 1H), 7.28 (d, J = 3.8 Hz, 4H), 7.12−6.98
(m, 1H), 6.93 (dd, J = 9.0, 2.5 Hz, 1H), 6.80 (d, J = 2.5 Hz, 1H), 6.58
(t, J = 5.9 Hz, 1H), 5.34 (s, 1H), 4.50 (s, 2H), 3.78 (s, 3H), 3.31 (q, J
= 6.8 Hz, 2H), 2.47 (s, 3H), 1.51 (p, J = 7.3 Hz, 2H), 1.39−1.33 (m,
2H), 0.92 (t, J = 7.3 Hz, 3H) ppm. 13C{1H} NMR (126 MHz,
Chloroform-d) δ 168.7, 162.8, 154.4, 140.2, 139.1, 131.0, 130.7,
129.0, 128.0, 116.8, 112.6, 107.9, 102.2, 55.9, 55.6, 39.4, 31.6, 21.3,
20.1, 13.8 ppm.
N-(2-(Cyclohexylamino)-2-oxoethyl)-6-methoxy-N-phenyl-1H-
indole-2-carboxamide (5n). Synthesized according to procedure A in
1 mmol scale, with puriﬁcation of the crude product by column
chromatography (silica gel; 80% ethyl acetate in petroleum ether) to
aﬀord 5n (361 mg, 85%) as a yellow solid. 1H NMR (500 MHz,
Chloroform-d) δ 9.21 (s, 1H), 7.50 (q, J = 2.9 Hz, 3H), 7.45−7.33
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(m, 2H), 7.24 (d, J = 8.8 Hz, 1H), 6.80 (d, J = 2.3 Hz, 1H), 6.72 (dd,
J = 8.8, 2.2 Hz, 1H), 6.43 (d, J = 8.3 Hz, 1H), 5.25 (d, J = 2.2 Hz,
1H), 4.48 (s, 2H), 3.85 (s, 3H), 2.04−1.88 (m, 2H), 1.72 (dt, J =
13.4, 4.1 Hz, 3H), 1.66−1.53 (m, 1H), 1.39 (q, J = 12.5 Hz, 2H), 1.21
(qd, J = 10.4, 9.1, 3.8 Hz, 3H) ppm. 13C{1H} NMR (126 MHz,
Chloroform-d) δ 167.7, 162.7, 158.7, 142.8, 136.5, 130.1, 129.0,
128.4, 127.5, 123.3, 122.0, 112.1, 108.6, 93.2, 55.7, 55.5, 48.2, 33.0,
25.5, 24.7 ppm.
N-(2-((2,3-Dimethoxybenzyl)amino)-2-oxoethyl)-6-methoxy-N-
(p-tolyl)-1H-indole-2-carboxamide (5o). Synthesized according to
procedure A in 1 mmol scale, with puriﬁcation of the crude product
by column chromatography (silica gel; 70% ethyl acetate in petroleum
ether) to aﬀord 5o (419 mg, 86%) as a yellow solid. 1H NMR (500
MHz, Chloroform-d) δ 9.18 (s, 1H), 7.28−7.21 (m, 4H), 7.01 (t, J =
7.9 Hz, 1H), 6.89 (ddd, J = 19.8, 7.7, 1.5 Hz, 4H), 6.79 (d, J = 2.3 Hz,
1H), 6.71 (dd, J = 8.8, 2.2 Hz, 1H), 5.34−5.29 (m, 1H), 4.53 (t, J =
5.3 Hz, 3H), 4.49 (s, 2H), 3.90 (d, J = 3.7 Hz, 2H), 3.86 (s, 6H), 3.84
(s, 3H), 2.46 (s, 3H) ppm. 13C{1H} NMR (126 MHz, Chloroform-d)
δ 168.5, 162.7, 158.6, 152.6, 147.2, 140.2, 138.9, 136.5, 131.7, 130.7,
128.1, 127.7, 124.2, 123.2, 121.3, 112.0, 112.0, 108.5, 93.3, 60.7, 55.8,
55.6, 55.5, 38.9, 21.3 ppm.
5-Chloro-N-(2-((1-(4-methoxyphenyl)ethyl)amino)-2-oxoethyl)-
N-phenyl-1H-indole-2-carboxamide (5p). Synthesized according to
procedure A in 1 mmol scale, with puriﬁcation of the crude product
by column chromatography (silica gel; 60% ethyl acetate in petroleum
ether) to aﬀord 5p (379 mg, 82%) as a yellow solid. 1H NMR (500
MHz, Chloroform-d) δ 9.57 (s, 1H), 7.56−7.42 (m, 3H), 7.39−7.29
(m, 4H), 7.26−7.21 (m, 2H), 7.19 (dd, J = 8.8, 2.0 Hz, 1H), 6.89−
6.77 (m, 2H), 6.66 (d, J = 8.1 Hz, 1H), 5.22 (d, J = 2.1 Hz, 1H),
5.16−5.08 (m, 1H), 4.60−4.42 (m, 2H), 3.78 (s, 3H), 1.50 (d, J = 6.9
Hz, 3H) ppm. 13C{1H} NMR (126 MHz, Chloroform-d) δ 167.3,
162.4, 158.8, 142.5, 135.1, 133.8, 130.1, 129.8, 129.2, 128.5, 128.4,
127.3, 126.0, 125.5, 121.5, 114.0, 112.8, 107.5, 55.6, 55.3, 48.4, 21.8
ppm.
N-(2-oxo-2-((2,4,4-trimethylpentan-2-yl)amino)ethyl)-N-(o-
tolyl)-1H-indole-2-carboxamide (5q). Synthesized according to
procedure A in 1 mmol scale, with puriﬁcation of the crude product
by column chromatography (silica gel; 30% ethyl acetate in petroleum
ether) to aﬀord 5q (332 mg, 79%) as a yellow solid. 1H NMR (500
MHz, Chloroform-d) δ 9.87 (s, 1H), 7.49−7.42 (m, 2H), 7.42−7.34
(m, 4H), 7.30−7.24 (m, 1H), 7.05 (t, J = 7.5 Hz, 1H), 6.72 (d, J = 5.6
Hz, 1H), 5.24 (q, J = 2.2 Hz, 1H), 4.85 (dd, J = 14.3, 8.2 Hz, 1H),
3.90 (dd, J = 14.8, 5.0 Hz, 1H), 2.25 (d, J = 1.8 Hz, 3H), 1.77 (d, J =
3.4 Hz, 2H), 1.46 (d, J = 2.4 Hz, 6H), 1.03(s, 9H) ppm. 13C{1H}
NMR (126 MHz, Chloroform-d) δ 167.4, 162.8, 141.7, 136.0, 135.7,
131.9, 129.5, 129.1, 128.7, 127.9, 127.8, 125.0, 122.5, 120.4, 111.7,
107.3, 56.3, 55.4, 52.1, 31.6, 31.5, 29.0, 17.7 ppm.
N-(2-(tert-Butylamino)-2-oxoethyl)-1-methyl-N-phenyl-1H-in-
dole-2-carboxamide (5r). Synthesized according to procedure A in 1
mmol scale, with puriﬁcation of the crude product by column
chromatography (silica gel; 50% ethyl acetate in petroleum ether) to
aﬀord 5r (284 mg, 78%) as a yellow solid. 1H NMR (500 MHz,
Chloroform-d) δ 7.42 (dt, J = 7.9, 1.0 Hz, 1H), 7.36−7.29 (m, 2H),
7.29−7.21 (m, 4H), 7.06 (ddd, J = 7.9, 6.8, 1.1 Hz, 1H), 6.27 (s, 1H),
6.11 (d, J = 0.8 Hz, 1H), 4.46 (s, 2H), 3.97 (s, 3H), 1.41 (s, 9H) ppm.
13C{1H} NMR (126 MHz, Chloroform-d) δ 167.7, 164.2, 143.8,
138.1, 131.2, 129.5, 127.5, 127.0, 126.1, 123.9, 122.0, 120.1, 109.8,
108.1, 55.7, 51.4, 31.7, 28.8 ppm.
N-(tert-Butyl)-2-(6-oxo-6,11-dihydro-5H-indolo[3,2-c]quinolin-5-
yl)acetamide (6a). Synthesized according to procedure B in 0.3
mmol scale, with puriﬁcation of the crude product by column
chromatography (silica gel; 40% ethyl acetate in petroleum ether) to
aﬀord 6a (81 mg, 78%) as an oﬀ-white solid; mp: 364−366 °C. 1H
NMR (500 MHz, DMSO-d6) δ 12.61 (s, 1H), 8.40−8.17 (m, 2H),
7.99 (s, 1H), 7.67−7.57 (m, 2H), 7.42−7.28 (m, 4H), 5.03 (s, 2H),
1.30 (d, J = 1.7 Hz, 9H) ppm. 13C{1H} NMR (126 MHz, DMSO-d6)
δ 167.1, 159.5, 140.4, 139.1, 138.3, 130.0, 125.1, 124.6, 123.1, 122.1,
121.6, 121.2, 115.9, 113.4, 112.1, 106.0, 50.9, 44.3, 28.9. HRMS
(ESI)calcd for C21H22N3O2 [M + H]
+, 348.1712; found, 348.1711.
N-(tert-Butyl)-2-(2-chloro-6-oxo-6,11-dihydro-5H-indolo[3,2-c]-
quinolin-5-yl)acetamide (6b). Synthesized according to procedure B
in 0.3 mmol scale, with puriﬁcation of the crude product by column
chromatography (silica gel; 60% ethyl acetate in petroleum ether) to
aﬀord 6b (63 mg, 55%) as an oﬀ-white solid; mp: 353−355 °C. 1H
NMR (500 MHz, DMSO-d6) δ 12.67 (s, 1H), 8.41 (d, J = 2.5 Hz,
1H), 8.22 (d, J = 7.9 Hz, 1H), 8.01 (s, 1H), 7.68−7.62 (m, 2H), 7.42
(ddd, J = 8.3, 7.1, 1.3 Hz, 1H), 7.35 (d, J = 9.1 Hz, 1H), 7.33−7.29
(m, 1H), 5.02 (s, 2H), 1.29 (s, 9H) ppm. 13C{1H} NMR (126 MHz,
DMSO-d6) δ 166.8, 159.3, 139.1, 138.3, 137.8, 129.5 (d, J = 18.6 Hz),
126.4, 125.4−124.9 (m), 124.8, 122.3, 121.9, 121.3, 118.5−117.4
(m), 114.7, 112.4, 106.7, 50.9, 44.4, 29.0 ppm. HRMS (ESI) calcd for
C21H21ClN3O2 [M + H]
+, 382.1322; found, 382.1323.
N-(tert-Butyl)-2-(2-methyl-6-oxo-6,11-dihydro-5H-indolo[3,2-c]-
quinolin-5-yl)acetamide (6c). Synthesized according to procedure B
in 0.3 mmol scale, with puriﬁcation of the crude product by column
chromatography (silica gel; 40% ethyl acetate in petroleum ether) to
aﬀord 6c (63 mg, 58%) as a yellow solid; mp: 348−349 °C. 1H NMR
(500 MHz, DMSO-d6) δ 12.56 (s, 1H), 8.21 (d, J = 7.8 Hz, 1H),
8.13−8.08 (m, 1H), 7.96 (s, 1H), 7.63 (d, J = 8.1 Hz, 1H), 7.46−7.35
(m, 2H), 7.32−7.21 (m, 2H), 5.00 (s, 2H), 2.46 (s, 3H), 1.29 (s, 9H)
ppm. 13C{1H} NMR (126 MHz, DMSO-d6) δ 167.1, 159.5, 140.3,
138.3, 137.1, 131.2, 131.1−130.7 (m), 125.1, 124.6, 122.9, 121.6,
121.2, 115.8, 113.3, 112.2, 106.1, 50.9, 44.3, 29.0, 20.8 ppm. HRMS
(ESI) calcd for C22H24N3O2 [M + H]
+, 362.1868; found, 362.1867.
N-(tert-Butyl)-2-(6-oxo-6,11-dihydro-5H-indolo[3,2-c]quinolin-5-
yl)-2-phenylacetamide (6d). Synthesized according to procedure B
in 0.3 mmol scale, with puriﬁcation of the crude product by column
chromatography (silica gel; 70% ethyl acetate in petroleum ether) to
aﬀord 6d (51 mg, 40%) as a yellow solid; mp: 323−325 °C. 1H NMR
(500 MHz, DMSO-d6) δ 12.67 (s, 1H), 8.26 (dd, J = 7.1, 2.3 Hz,
2H), 7.75 (s, 1H), 7.67 (d, J = 8.1 Hz, 1H), 7.41 (dddd, J = 11.7, 7.2,
5.0, 2.9 Hz, 3H), 7.35−7.27 (m, 5H), 7.27−7.18 (m, 3H), 1.28 (s,
9H) ppm. 13C{1H} NMR (126 MHz, DMSO-d6) δ 167.7, 160.2,
140.8, 138.4, 138.3, 137.5, 128.8, 128.5, 128.0, 127.4, 125.2, 124.7,
122.9, 122.2, 121.7, 121.3, 119.7, 114.1, 112.3, 105.9, 61.8−56.6 (m),




c]quinolin-5-yl)acetamide (6e). Synthesized according to procedure
B in 0.3 mmol scale, with puriﬁcation of the crude product by column
chromatography (silica gel; 60% ethyl acetate in petroleum ether) to
aﬀord 6e (84 mg, 64%) as a yellow solid; mp: 333−335 °C. 1H NMR
(500 MHz, DMSO-d6) δ 12.55 (s, 1H), 8.23 (d, J = 7.9 Hz, 1H), 8.02
(d, J = 2.6 Hz, 1H), 7.99 (s, 1H), 7.60 (d, J = 8.1 Hz, 1H), 7.47−7.41
(m, 2H), 7.41−7.34 (m, 3H), 7.29 (t, J = 7.3 Hz, 1H), 7.18 (dd, J =
7.9, 6.7 Hz, 1H), 7.13−7.08 (m, 2H), 5.03 (s, 2H), 1.31 (s, 9H) ppm.
13C{1H} NMR (126 MHz, DMSO-d6) δ 167.0, 159.3, 157.9, 151.2,
139.7, 138.3, 135.6, 130.6, 125.0, 124.8, 123.8, 121.8, 121.7, 121.4,
118.5, 117.9, 114.4, 112.6, 112.3, 106.5, 50.9, 44.5, 29.0 ppm. HRMS
(ESI)calcd for C27H26N3O3 [M + H]
+, 440.1974; found, 440.1969.
N-(tert-Butyl)-2-(1,3-dimethyl-6-oxo-6,11-dihydro-5H-indolo-
[3,2-c]quinolin-5-yl)acetamide (6f). Synthesized according to
procedure B in 0.3 mmol scale, with puriﬁcation of the crude
product by column chromatography (silica gel; 40% ethyl acetate in
petroleum ether) to aﬀord 6f (47 mg, 42%) as a yellow solid; mp:
338−340 °C. 1H NMR (500 MHz, DMSO-d6) δ 11.44 (s, 1H), 8.28
(d, J = 7.8 Hz, 1H), 8.01 (s, 1H), 7.80 (d, J = 8.1 Hz, 1H), 7.37 (td, J
= 8.1, 7.6, 1.3 Hz, 1H), 7.29 (t, J = 7.5 Hz, 1H), 7.04 (d, J = 4.1 Hz,
2H), 5.77 (s, 1H), 5.03 (s, 2H), 2.95 (s, 3H), 2.41 (s, 3H), 1.30 (s,
9H) ppm. 13C{1H} NMR (126 MHz, DMSO-d6) δ 167.2, 159.4,
140.0, 139.8, 138.8, 138.5, 134.4, 126.0, 124.4, 124.2, 121.7, 121.0,
120.9, 114.3, 112.9, 110.9, 106.3, 50.9, 44.7, 29.0, 23.4, 21.9 ppm.




quinolin-5-yl)acetamide (6g). Synthesized according to procedure B
in 0.3 mmol scale, with puriﬁcation of the crude product by column
chromatography (silica gel; 60% ethyl acetate in petroleum ether) to
aﬀord 6g (65 mg, 59%) as an oﬀ-white solid; mp: 331−333 °C. 1H
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NMR (500 MHz, DMSO-d6) δ 12.63 (s, 1H), 8.23 (d, J = 7.8 Hz,
1H), 8.13 (dd, J = 9.1, 3.0 Hz, 1H), 8.00 (s, 1H), 7.66 (d, J = 8.1 Hz,
1H), 7.51 (ddd, J = 11.2, 8.4, 3.0 Hz, 1H), 7.42 (ddd, J = 8.3, 7.1, 1.3
Hz, 1H), 7.37 (dd, J = 9.4, 4.5 Hz, 1H), 7.34−7.28 (m, 1H), 5.03 (s,
2H), 1.29 (s, 9H) ppm. 13C{1H} NMR (126 MHz, DMSO-d6) δ
166.9, 1593, 158.4, 156.5, 139.5, 138.3, 135.9, 125.1, 124.9, 121.9,
121.4, 118.1, 114.2 (d, J = 9.0 Hz), 112.3, 108.6, 106.7, 50.8, 44.5,




indolo[3,2-c]quinolin-5-yl)acetamide (6h). Synthesized according to
procedure B in 0.3 mmol scale, with puriﬁcation of the crude product
by column chromatography (silica gel; 50% ethyl acetate in petroleum
ether) to aﬀord 6h (49 mg, 35%) as a yellow solid; mp: 328−330 °C.
1H NMR (500 MHz, Chloroform-d) δ 10.84 (s, 1H), 8.08−8.02 (m,
2H), 7.60−7.54 (m, 2H), 7.46−7.41 (m, 2H), 7.41−7.33 (m, 3H),
7.33−7.30 (m, 1H), 7.25−7.18 (m, 3H), 6.22 (s, 1H), 1.28 (s, 9H)
ppm. 13C{1H} NMR (126 MHz, Chloroform-d) δ 166.6, 163.7, 147.7,
144.0, 142.4, 136.8, 132.1, 131.4, 129.8, 129.2, 127.6, 126.9, 126.2,
123.3, 122.0, 120.7, 113.9, 75.3, 52.4, 28.5 ppm. HRMS (ESI)calcd
for C27H25N4O4 [M + H]
+, 469.1876; found, 469.1866.
N-(tert-Butyl)-2-(4-nitrophenyl)-2-(6-oxo-6,11-dihydro-5H-
indolo[3,2-c]quinolin-5-yl)acetamide (6i). Synthesized according to
procedure B in 0.3 mmol scale, with puriﬁcation of the crude product
by column chromatography (silica gel; 50% ethyl acetate in petroleum
ether) to aﬀord 6i (66 mg, 55%) as a yellow solid; mp: 349−351 °C.
1H NMR (500 MHz, Chloroform-d) δ 9.71 (s, 1H), 8.41 (d, J = 7.7
Hz, 1H), 7.93 (dd, J = 7.8, 1.5 Hz, 1H), 7.89 (s, 1H), 7.71 (d, J = 8.6
Hz, 1H), 7.55 (d, J = 8.0 Hz, 1H), 7.40 (tdd, J = 8.1, 3.7, 1.4 Hz, 2H),
7.37−7.33 (m, 1H), 7.26 (d, J = 7.6 Hz, 1H), 3.32 (dt, J = 12.5, 6.0
Hz, 2H), 1.70 (d, J = 57.9 Hz, 6H), 1.37 (s, 9H) ppm. 13C{1H} NMR
(126 MHz, Chloroform-d) δ 174.2, 164.4, 140.1, 139.9, 137.6, 127.8,
125.0, 124.7, 122.3, 122.1, 121.7, 121.3, 120.3, 114.9, 111.3, 109.3,
75.8, 51.1, 39.2, 28.6, 23.7 ppm. HRMS (ESI) calcd for C25H28N3O2
[M + H]+, 402.2182; found, 402.2180.
2-(8-Chloro-6-oxo-6,11-dihydro-5H-indolo[3,2-c]quinolin-5-yl)-
N-(4-methoxyphenethyl)acetamide (6j). Synthesized according to
procedure B in 0.3 mmol scale, with puriﬁcation of the crude product
by column chromatography (silica gel; 50% ethyl acetate in petroleum
ether) to aﬀord 6j (106 mg, 77%) as a yellow solid; mp: 316−318 °C.
1H NMR (500 MHz, DMSO-d6) δ 12.83 (s, 1H), 8.31−8.21 (m, 2H),
8.16 (d, J = 2.1 Hz, 1H), 7.66 (d, J = 8.6 Hz, 1H), 7.60 (ddd, J = 8.6,
7.2, 1.5 Hz, 1H), 7.41 (ddd, J = 7.5, 4.4, 2.2 Hz, 2H), 7.28 (d, J = 8.6
Hz, 1H), 7.15−7.09 (m, 2H), 6.87−6.82 (m, 2H), 5.02 (s, 2H), 3.72
(s, 3H), 3.32−3.26 (m, 2H), 2.66 (t, J = 7.2 Hz, 2H) ppm. 13C{1H}
NMR (126 MHz, DMSO-d6) δ 167.7, 159.3, 158.1, 141.6, 139.2,
136.8, 131.6, 130.1, 126.2, 126.2, 124.6, 123.3, 122.5, 120.2, 116.1,
114.2 (d, J = 9.9 Hz), 114.0, 113.8, 113.3, 105.6, 55.4 (d, J = 10.5
Hz), 44.4, 41.0, 34.7 ppm. HRMS (ESI) calcd for C26H23ClN3O3[M
+ H]+, 460.1428; found, 460.1406.
tert-Butyl(5-(2-(benzylamino)-2-oxoethyl)-6-oxo-6,11-dihydro-
5H-indolo[3,2-c]quinolin-2-yl)carbamate (6k). Synthesized accord-
ing to procedure B in 0.3 mmol scale, with puriﬁcation of the crude
product by column chromatography (silica gel; 40% ethyl acetate in
petroleum ether) to aﬀord 6k (73 mg, 49%) as a brown solid; mp:
289−291 °C. 1H NMR (500 MHz, DMSO-d6) δ 12.68 (s, 1H), 9.57
(s, 1H), 8.69 (t, J = 6.0 Hz, 1H), 8.57 (s, 1H), 8.22 (d, J = 7.8 Hz,
1H), 7.63 (d, J = 8.1 Hz, 1H), 7.39 (ddd, J = 8.4, 5.4, 1.9 Hz, 2H),
7.37−7.29 (m, 4H), 7.29−7.26 (m, 3H), 5.10 (s, 2H), 4.32 (d, J = 6.0
Hz, 2H), 1.55 (s, 9H) ppm. 13C{1H} NMR (126 MHz, DMSO-d6) δ
168.3, 159.3, 153.5, 140.3, 139.8, 138.5, 134.5, 134.4, 128.7, 127.7,
127.3, 125.1, 124.6, 121.6, 121.2, 116.5, 113.7, 112.5, 112.3, 106.4,
79.7, 44.5, 42.7, 28.7 (d, J = 13.6 Hz) ppm. HRMS (ESI) calcd for
C29H29N4O4 [M + H]
+, 497.2188; found, 497.2178.
N-(tert-Butyl)-2-(2,9-dimethoxy-6-oxo-6,11-dihydro-5H-indolo-
[3,2-c]quinolin-5-yl)acetamide (6l). Synthesized according to
procedure B in 0.3 mmol scale, with puriﬁcation of the crude
product by column chromatography (silica gel; 60% ethyl acetate in
petroleum ether) to aﬀord 6l (88 mg, 72%) as an oﬀ-white solid; mp:
341−343 °C. 1H NMR (500 MHz, DMSO-d6) δ 12.40 (s, 1H), 8.07
(d, J = 8.6 Hz, 1H), 7.95 (s, 1H), 7.82 (d, J = 2.8 Hz, 1H), 7.26 (d, J =
9.3 Hz, 1H), 7.19 (dd, J = 9.2, 2.8 Hz, 1H), 7.10 (d, J = 2.2 Hz, 1H),
6.94 (dd, J = 8.6, 2.3 Hz, 1H), 4.98 (s, 2H), 3.90 (s, 3H), 3.88 (s,
3H), 1.29 (s, 9H) ppm. 13C{1H} NMR (126 MHz, Chloroform-d) δ
167.2, 159.0, 157.9, 154.6, 139.5, 139.4, 133.1, 121.9, 119.0, 117.5,
117.2, 114.1, 111.1, 106.6, 105.3, 95.6, 56.1, 55.8, 50.9, 44.4, 29.0




[3,2-c]quinolin-5-yl)acetamide (6m). Synthesized according to
procedure B in 0.3 mmol scale, with puriﬁcation of the crude
product by column chromatography (silica gel; 10% methanol in
dichloromethane) to aﬀord 6m (74 mg, 63%) as a yellow solid; mp:
325−327 °C. 1H NMR (500 MHz, DMSO-d6) δ 12.43 (s, 1H), 8.15
(t, J = 5.7 Hz, 1H), 8.07 (s, 1H), 7.70 (d, J = 2.6 Hz, 1H), 7.52 (d, J =
8.7 Hz, 1H), 7.39 (d, J = 8.3 Hz, 1H), 7.23 (d, J = 8.6 Hz, 1H), 7.01
(dd, J = 8.8, 2.6 Hz, 1H), 5.00 (s, 2H), 3.84 (s, 3H), 3.09 (q, J = 6.6
Hz, 2H), 2.45 (s, 3H), 1.42−1.38 (m, 2H), 1.30−1.26 (m, 2H), 0.87
(t, J = 7.3 Hz, 3H) ppm. 13C{1H} NMR (126 MHz, DMSO-d6) δ
167.8, 159.5, 155.2, 140.6, 137.0, 133.0, 131.2, 130.8, 125.8, 122.7,
115.9, 114.2, 113.6, 113.0, 106.1, 103.0 (d, J = 27.6 Hz), 55.8 (d, J =
25.5 Hz), 44.3, 38.8, 31.7, 20.9, 20.0, 14.1 ppm. HRMS (ESI) calcd
for C23H26N3O3 [M + H]
+, 392.1974; found, 392.1967.
N-Cyclohexyl-2-(9-methoxy-6-oxo-6,11-dihydro-5H-indolo[3,2-
c]quinolin-5-yl)acetamide (6n). Synthesized according to procedure
B in 0.3 mmol scale, with puriﬁcation of the crude product by column
chromatography (silica gel; 8% methanol in dichloromethane) to
aﬀord 6n (58 mg, 48%) as a yellow solid; mp: 307−309 °C. 1H NMR
(500 MHz, DMSO-d6) δ 12.47 (s, 1H), 8.24 (dd, J = 7.9, 1.6 Hz,
1H), 8.17 (d, J = 7.9 Hz, 1H), 8.07 (d, J = 8.6 Hz, 1H), 7.56 (ddd, J =
8.6, 7.1, 1.5 Hz, 1H), 7.39−7.30 (m, 2H), 7.10 (d, J = 2.3 Hz, 1H),
6.94 (dd, J = 8.6, 2.3 Hz, 1H), 5.04 (s, 2H), 3.88 (s, 3H), 1.80−1.67
(m, 4H), 1.56 (d, J = 12.4 Hz, 1H), 1.24 (q, J = 12.9 Hz, 6H) ppm.
13C{1H} NMR (126 MHz, DMSO) δ 166.9, 159.4, 157.9, 139.8,
139.4, 138.6, 129.3, 122.7, 122.1, 121.9, 118.9, 115.9, 113.6, 111.2,
106.3, 95.6, 55.9, 48.2, 44.2, 32.9, 25.6, 24.9 ppm. HRMS (ESI) calcd
for C24H26N3O3 [M + H]
+, 404.1974; found, 404.1971.
N-(2,3-Dimethoxybenzyl)-2-(9-methoxy-2-methyl-6-oxo-6,11-di-
hydro-5H-indolo[3,2-c]quinolin-5-yl)acetamide (6o). Synthesized
according to procedure B in 0.3 mmol scale, with puriﬁcation of
the crude product by column chromatography (silica gel; 70% ethyl
acetate in petroleum ether) to aﬀord 6o (86 mg, 59%) as a yellow
solid; mp: 283−285 °C. 1H NMR (500 MHz, DMSO-d6) δ 12.44 (s,
1H), 8.58 (t, J = 5.9 Hz, 1H), 8.09−8.03 (m, 2H), 7.38 (dd, J = 8.7,
2.0 Hz, 1H), 7.28 (d, J = 8.7 Hz, 1H), 7.09 (d, J = 2.2 Hz, 1H), 7.04
(t, J = 7.9 Hz, 1H), 6.94 (ddd, J = 17.2, 8.4, 1.9 Hz, 2H), 6.84 (dd, J =
7.7, 1.6 Hz, 1H), 5.10 (s, 2H), 4.31 (d, J = 5.7 Hz, 2H), 3.87 (s, 3H),
3.80 (s, 3H), 3.73 (d, J = 6.5 Hz, 3H), 2.47 (s, 3H) ppm. 13C{1H}
NMR (126 MHz, Chloroform-d) δ 168.2, 159.3, 157.9, 152.7, 146.6,
139.7, 139.4, 136.6, 132.9, 131.2, 130.4, 124.3, 122.6, 121.8, 120.6,
119.0, 115.9, 113.6, 112.1, 111.1, 106.3, 95.6, 60.5, 56.2, 44.4, 37.5,




N-(1-(4-methoxyphenyl)ethyl)acetamide (6p). Synthesized accord-
ing to procedure B in 0.3 mmol scale, with puriﬁcation of the crude
product by column chromatography (silica gel; 60% ethyl acetate in
petroleum ether) to aﬀord 6p (90 mg, 65%) as a yellow solid; mp:
326−328 °C. 1H NMR (500 MHz, DMSO-d6) δ 12.82 (s, 1H), 8.71
(d, J = 8.0 Hz, 1H), 8.28 (dd, J = 7.9, 1.6 Hz, 1H), 8.15 (d, J = 2.2 Hz,
1H), 7.66 (d, J = 8.6 Hz, 1H), 7.60 (ddd, J = 8.7, 7.2, 1.5 Hz, 1H),
7.41 (dd, J = 8.5, 2.1 Hz, 2H), 7.35 (d, J = 8.6 Hz, 1H), 7.29−7.24
(m, 2H), 6.93−6.87 (m, 2H), 5.10 (d, J = 14.1 Hz, 2H), 4.97−4.86
(m, 1H), 3.75 (s, 3H), 1.38 (d, J = 7.0 Hz, 3H) ppm. 13C{1H} NMR
(126 MHz, DMSO-d6) δ 166.9, 159.3, 158.5, 141.6, 139.2, 136.8 (d, J
= 6.2 Hz), 130.4 (d, J = 23.4 Hz), 127.6, 126.2, 124.6, 123.3, 122.4,
120.2, 116.2, 114.0, 114.0, 113.8, 113.2, 105.6, 55.6, 48.0 (d, J = 6.9
Hz), 44.2, 22.9 (d, J = 18.3 Hz) ppm. HRMS (ESI)calcd for
C26H23ClN3O3 [M + H]
+, 460.1428; found, 460.1423.
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2-(4-Methyl-6-oxo-6,11-dihydro-5H-indolo[3,2-c]quinolin-5-yl)-
N-(2,4,4-trimethylpentan-2-yl)acetamide (6q). Synthesized accord-
ing to procedure B in 0.3 mmol scale, with puriﬁcation of the crude
product by column chromatography (silica gel; 50% ethyl acetate in
petroleum ether) to aﬀord 6q (70 mg, 56%) as a yellow solid; mp:
326−328 °C. 1H NMR (500 MHz, DMSO-d6) δ 12.47 (s, 1H), 8.22−
8.10 (m, 2H), 7.65−7.58 (m, 2H), 7.43−7.35 (m, 2H), 7.28 (td, J =
7.4, 1.0 Hz, 2H), 5.03 (s, 2H), 2.70 (s, 3H), 1.71 (s, 2H), 1.34 (s,
6H), 0.99 (s, 9H) ppm. 13C{1H} NMR (126 MHz, DMSO-d6) δ
168.2, 161.3, 141.2, 140.1, 138.4, 135.0, 125.9, 124.9, 124.6, 122.5,
121.6, 121.3, 115.2, 112.2, 112.1, 105.8, 54.6, 50.8, 49.2, 31.7, 29.7,




c]quinolin-5-yl)acetamide (6r). Synthesized according to procedure
B in 0.3 mmol scale, with puriﬁcation of the crude product by column
chromatography (silica gel; 50% ethyl acetate in petroleum ether) to
aﬀord 6r (74 mg, 68%) as a yellow solid; mp: 282−284 °C. 1H NMR
(500 MHz, Chloroform-d) δ 8.52 (dd, J = 7.8, 1.6 Hz, 1H), 8.45 (d, J
= 8.2 Hz, 1H), 7.65 (dd, J = 8.4, 1.2 Hz, 1H), 7.61−7.58 (m, 2H),
7.52 (ddd, J = 8.5, 7.1, 1.5 Hz, 1H), 7.48−7.40 (m, 2H), 7.29 (s, 1H),
5.01 (s, 2H), 4.41 (s, 3H), 1.30 (s, 9H) ppm. 13C{1H} NMR (126
MHz, Chloroform-d) δ 167.5, 157.1, 141.0, 135.6, 126.9, 126.5, 125.6,
123.8, 123.4, 122.9, 121.7, 121.3, 119.8, 119.6, 115.8, 110.7, 51.5,





The Supporting Information is available free of charge on the
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NMR spectra, docking procedure, and crystal structure
determinations (PDF)
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